Pharmacotherapeutic strategies for patients treated for depression in UK primary care: a database analysis

References

• Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) surveys. Int J Methods Psychiatr Res 2003;12:3-21
   PubMed Web of Science ®Google Scholar
• Smith DJ, Nicholl BI, Cullen B, et al. Prevalence and characteristics of probable major depression and bipolar disorder within UK Biobank: cross-sectional study of 172,751 participants. PLoS One 2013;8:e75362
   PubMed Web of Science ®Google Scholar
• Moussavi S, Chatterji S, Verdes E, et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370:851-8
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet 2013;382:1575-86
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997;349:1498-504
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder, 3rd edn. Arlington, VA: American Psychiatric Association, 2010
   Google Scholar
• Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 2009;25:161-75
   PubMed Web of Science ®Google Scholar
• Machado M, Einarson TR. Comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials. J Clin Pharm Ther 2010;35:177-88
   PubMed Web of Science ®Google Scholar
• Santaguida PL, MacQueen G, Keshavarz H, et al. Treatment for depression after unsatisfactory response to SSRIs. AHRQ Publication No.12-EHC050-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2012
   Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41
   PubMed Web of Science ®Google Scholar
• Thase ME, Pritchett YL, Ossanna MJ, et al. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007;27:672-6
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17
   PubMed Web of Science ®Google Scholar
• Rush AJ, Warden D, Wisniewski SR, et al. STAR*D: revising conventional wisdom. CNS Drugs 2009;23:627-47
   PubMed Web of Science ®Google Scholar
• Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-80
   PubMed Web of Science ®Google Scholar
• Druss BG, Schlesinger M, Allen HM Jr. Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population. Am J Psychiatry 2001;158:731-4
   PubMed Web of Science ®Google Scholar
• Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998;59:608-19
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Simon GE, Kalsekar A, et al. Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder. Depress Anxiety 2009;26:83-97
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998;50:97-108
   PubMed Web of Science ®Google Scholar
• Paykel ES. Partial remission, residual symptoms, and relapse in depression. Dialogues Clin Neurosci 2008;10:431-7
   PubMedGoogle Scholar
• Byford S, Barrett B, Despiegel N, Wade A. Impact of treatment success on health service use and cost in depression: longitudinal database analysis. Pharmacoeconomics 2011;29:157-70
   PubMed Web of Science ®Google Scholar
• Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341-7
   PubMed Web of Science ®Google Scholar
• Sobocki P, Ekman M, Agren H, et al. The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression. Int J Clin Pract 2006;60:791-8
   PubMed Web of Science ®Google Scholar
• Simon GE, Revicki D, Heiligenstein J, et al. Recovery from depression, work productivity, and health care costs among primary care patients. Gen Hosp Psychiatry 2000;22:153-62
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Blanca-Tamayo M, Gutierrez-Nicuesa L, et al. [Impact of morbidity, resource use and costs on maintenance of remission of major depression in Spain: a longitudinal study in a population setting]. Gac Sanit 2010;24:13-9
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Clinical Guideline 23. Depression. Management of depression in primary and secondary care. 2004. Available at: http://www.nccmh.org.uk/downloads/Depression/cg023fullguideline.pdf [Last accessed 24 July 2014]
   Google Scholar
• NHS Information Centre for health and social care. Adult psychiatric morbidity in England, 2007. Results of a household survey. 2009. Available at: http://www.hscic.gov.uk/pubs/psychiatricmorbidity07 [Last accessed 24 July 2014]
   Google Scholar
• Social and General Statistics Section, House of Commons Library, London, UK. Cost of depression in England. 2011. Available at: http://wellbeingeconomics.files.wordpress.com/2012/02/costofdepressionstats2010.pdf [Last accessed 24 July 2014]
   Google Scholar
• King’s Fund, London, UK. Paying the price. The cost of mental health care in England to 2026. 2008. Available at: http://www.kingsfund.org.uk/sites/files/kf/Paying-the-Price-the-cost-of-mental-health-care-England-2026-McCrone-Dhanasiri-Patel-Knapp-Lawton-Smith-Kings-Fund-May-2008_0.pdf [Last accessed 24 July 2014]
   Google Scholar
• National Institute for Health and Clinical Excellence. NICE clinical guideline 90. Depression in adults. The treatment and management of depression in adults. 2009. Available at: http://www.nice.org.uk/guidance/cg90 [Last accessed 24 July 2014]
   Google Scholar
• Gaynes BN, Rush AJ, Trivedi MH, et al. The STAR*D study: treating depression in the real world. Cleve Clin J Med 2008;75:57-66
   PubMed Web of Science ®Google Scholar
• Warden D, Rush AJ, Trivedi MH, et al. The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449-59
   PubMedGoogle Scholar
• Schultz J, Joish V. Costs associated with changes in antidepressant treatment in a managed care population with major depressive disorder. Psychiatr Serv 2009;60:1604-11
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Perez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998;45:419-25
   PubMed Web of Science ®Google Scholar
• Campbell J, Dedman DJ, Eaton SC, et al. Is the CPRD GOLD population comparable to the U.K. population? Pharmacoepidemiol Drug Saf 2013;22(Suppl 1):280-1
   Google Scholar
• Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991;302:766-8
   PubMed Web of Science ®Google Scholar
• Jick H, Terris BZ, Derby LE, Jick SS. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Safety 1992;1:347-77
   Google Scholar
• Herrett E, Thomas SL, Schoonen WM, et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010;69:4-14
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Blanca-Tamayo M, Gutierrez-Nicuesa L, et al. Clinical validity of a population database definition of remission in patients with major depression. BMC Public Health 2010;10:64
   PubMed Web of Science ®Google Scholar
• Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004;25:119-42
   PubMedGoogle Scholar
• Garcia-Toro M, Medina E, Galan JL, et al. Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. BMC Psychiatry 2012;12:143
   PubMed Web of Science ®Google Scholar
• Fredman SJ, Fava M, Kienke AS, et al. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current ‘next-step’ practices. J Clin Psychiatry 2000;61:403-8
   PubMed Web of Science ®Google Scholar
• Shergill SS, Katona CL. Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. J Affect Disord 1997;43:19-25
   PubMed Web of Science ®Google Scholar
• Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol 2010;25:189-98
   PubMed Web of Science ®Google Scholar
• Sanglier T, Milea D, Saragoussi D, Toumi M. Increasing escitalopram dose is associated with fewer discontinuations than switch or combination approaches in patients initially on escitalopram 10 mg. Eur Psychiatry 2012;27:250-7
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. If at first you don’t succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs 2011;71:43-64
   PubMed Web of Science ®Google Scholar
• Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963-71
   PubMed Web of Science ®Google Scholar
• Khandker RK, Kruzikas DT, McLaughlin TP. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder. J Manag Care Pharm 2008;14:426-41
   PubMed Web of Science ®Google Scholar